| Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer R de Wit, J de Bono, CN Sternberg, K Fizazi, B Tombal, C Wülfing, ... New England Journal of Medicine 381 (26), 2506-2518, 2019 | 617 | 2019 |
| Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis F Pietrantonio, F Petrelli, A Coinu, M Di Bartolomeo, K Borgonovo, ... European journal of cancer 51 (5), 587-594, 2015 | 610 | 2015 |
| Metabolic phenotype of bladder cancer F Massari, C Ciccarese, M Santoni, R Iacovelli, R Mazzucchelli, F Piva, ... Cancer treatment reviews 45, 46-57, 2016 | 244 | 2016 |
| Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies S Antoun, E Lanoy, R Iacovelli, L Albiges‐Sauvin, Y Loriot, ... Cancer 119 (18), 3377-3384, 2013 | 232 | 2013 |
| Prognostic role of PD-L1 expression in renal cell carcinoma. A systematic review and meta-analysis R Iacovelli, F Nolè, E Verri, G Renne, C Paglino, M Santoni, ... Targeted oncology 11, 143-148, 2016 | 199 | 2016 |
| The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer R Iacovelli, C Ciccarese, E Bria, M Romano, E Fantinel, D Bimbatti, ... Clinical genitourinary cancer 16 (3), e645-e653, 2018 | 161 | 2018 |
| Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis S Bracarda, R Iacovelli, L Boni, M Rizzo, L Derosa, M Rossi, L Galli, ... Annals of Oncology 26 (10), 2107-2113, 2015 | 129 | 2015 |
| Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials R Iacovelli, D Alesini, A Palazzo, P Trenta, M Santoni, L De Marchis, ... Cancer treatment reviews 40 (2), 271-275, 2014 | 113 | 2014 |
| Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma G Ianiro, E Rossi, AM Thomas, G Schinzari, L Masucci, G Quaranta, ... Nature communications 11 (1), 4333, 2020 | 106 | 2020 |
| First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis F Pietrantonio, C Cremolini, F Petrelli, M Di Bartolomeo, F Loupakis, ... Critical reviews in oncology/hematology 96 (1), 156-166, 2015 | 100 | 2015 |
| Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors M Santoni, A Conti, S Partelli, C Porta, CN Sternberg, G Procopio, ... Annals of Surgical Oncology 22, 2094-2100, 2015 | 96 | 2015 |
| Clinical and pathological features of primary neuroectodermal tumor/Ewing sarcoma of the kidney E Risi, R Iacovelli, A Altavilla, D Alesini, A Palazzo, C Mosillo, P Trenta, ... Urology 82 (2), 382-386, 2013 | 96 | 2013 |
| Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma M Santoni, U De Giorgi, R Iacovelli, A Conti, L Burattini, L Rossi, ... British journal of cancer 109 (7), 1755-1759, 2013 | 95 | 2013 |
| Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials R Iacovelli, A Palazzo, S Mezi, F Morano, G Naso, E Cortesi Acta Oncologica 51 (7), 873-879, 2012 | 94 | 2012 |
| Molecular markers in circulating tumour cells from metastatic colorectal cancer patients P Gazzaniga, A Gradilone, A Petracca, C Nicolazzo, C Raimondi, ... Journal of cellular and molecular medicine 14 (8), 2073-2077, 2010 | 93 | 2010 |
| Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET … C Ferté, S Koscielny, L Albiges, L Rocher, JC Soria, R Iacovelli, Y Loriot, ... European urology 65 (4), 713-720, 2014 | 86 | 2014 |
| Prostate cancer heterogeneity: Discovering novel molecular targets for therapy C Ciccarese, F Massari, R Iacovelli, M Fiorentino, R Montironi, ... Cancer Treatment Reviews 54, 68-73, 2017 | 84 | 2017 |
| Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort R Iacovelli, G Cartenì, CN Sternberg, M Milella, M Santoni, G Di Lorenzo, ... European journal of cancer 49 (9), 2134-2142, 2013 | 84 | 2013 |
| Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies R Iacovelli, F Pietrantonio, A Farcomeni, C Maggi, A Palazzo, F Ricchini, ... PLoS One 9 (9), e108940, 2014 | 79 | 2014 |
| DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan FS Falvella, S Cheli, A Martinetti, C Mazzali, R Iacovelli, C Maggi, ... British journal of clinical pharmacology 80 (3), 581-588, 2015 | 77 | 2015 |
Chiara CiccareseMedical Oncology, Department of Medical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, RomeVerified email at guest.policlinicogemelli.it